<DOC>
	<DOCNO>NCT02534935</DOCNO>
	<brief_summary>The purpose study investigate immunogenicity , safety tolerability new vaccine might prevent meningococcal B disease . The study conduct healthy toddler age 12 24 month .</brief_summary>
	<brief_title>Immunogenicity , Safety Tolerability Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine ( Bivalent rLP2086 ) Healthy Toddlers .</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female subject age 12 &lt; 15 month 18 &lt; 24 month sentinelcohort enrollment , Or,12 &lt; 24 month expandedcohort enrollment . Subjects must receive vaccination relevant National Immunization Program ( NIP ) age group . Subject determine good health medical history , physical examination , judgment investigator . Previous vaccination meningococcal serogroup B vaccine . Previous vaccination HAV vaccine , requirement receive nonstudy HAV vaccine Stage 1 study . Contraindication vaccination HAV vaccine know latex allergy . A previous anaphylactic reaction vaccine vaccinerelated component . Bleeding diathesis condition associate prolonged bleeding time would contraindicate intramuscular injection . A know suspected disorder immune system would prevent immune response vaccine , subject congenital acquire defect Bcell function receive systemic immunosuppressive therapy . Subjects terminal complement deficiency may include . History microbiologically proven disease cause N meningitidis Neisseria gonorrhoeae . Significant neurologic disorder history seizure ( exclude simple febrile seizure ) . Receipt blood product , include immunoglobulin , within 6 month first study vaccination end Stage 1 . Current chronic use systemic antibiotic . Received investigational drug , vaccine device within 28 day administration first study vaccination and/or study participation . Any neuroinflammatory autoimmune condition , include limited transverse myelitis , uveitis , optic neuritis , multiple sclerosis .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Phase 2 Immunogenicity</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability Study</keyword>
	<keyword>rLP2086 Vaccine</keyword>
	<keyword>Healthy Toddlers</keyword>
	<keyword>Neisseria meningitidis</keyword>
	<keyword>Duration Immunogenicity</keyword>
</DOC>